个体化胸部放疗在埃克替尼治疗有效的Ⅳ期NSCLC患者中的临床价值

Clinical value of individualized chest radiotherapy in patients with stage Ⅳ NSCLC treated effectively with ektinib

目的探讨个体化胸部放疗在埃克替尼治疗有效的Ⅳ期非小细胞肺癌(NSCLC)患者中的临床价值。方法回顾性分析2017年1月至2018年6月本院59例埃克替尼治疗有效患者的临床资料,按治疗方案的不同将患者分为对照组(29例)和研究组(30例)。对照组单纯应用埃克替尼治疗,研究组采取埃克替尼联合个体化胸部放疗。比较两组患者的病情控制效果及中位无进展生存时间。结果研究组的客观缓解率显著高于对照组,差异有统计学意义(P<0.05);研究组的中位无进展生存时间是(15.15±1.32)个月,显著长于对照组的(13.19±1.06)个月,差异有统计学意义(P<0.05)。结论个体化胸部放疗对埃克替尼治疗有效的Ⅳ期NSCLC患者的治疗效果更佳,并能延长患者无进展生存期,值得借鉴。

Objective To investigate the clinical value of individualized chest radiotherapy in patients with stage Ⅳ non-small cell lung cancer (NSCLC) treated effectively with ectinib. Methods The clinical data of 59 patients treated effectively with ektinib in our hospital from January 2017 to June 2018 were retrospectively analyzed. The patients were divided into control group (29 cases) and research group (30 cases) according to different treatment schemes. The control group was treated with ektinib alone, while the research group was treated with ektinib combined with individualized chest radiotherapy. The effectiveness of disease control and median progression-free survival time were compared between the two groups. Results The objective remission rate in the research group was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). The median progression-free survival time in the research group was (15.15±1.32) months, which was significantly longer than (13.19±1.06) months in the control group, and the difference was statistically significant (P<0.05). Conclusion Individualized chest radiotherapy is more effective for patients with stage Ⅳ NSCLC treated effectively with ektinib, which can prolong the progression-free survival of patients. It is worth learning.